603658.SH
Autobio Diagnostics Co., Ltd.
SSE · Healthcare · Medical - Diagnostics & Research · CN
CNY 34.08
−1.50%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 4.2B | 4.2B | 4.5B | 4.4B | 4.4B |
| Cost of Revenue | 1.4B | 1.5B | 1.5B | 1.6B | 1.8B |
| Gross Profit | 2.8B | 2.8B | 2.9B | 2.9B | 2.7B |
| Operating Expenses | |||||
| R&D Expense | 558.7M | 555.1M | 731.9M | 656.1M | 568.5M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 253.4M | 241.3M | 210.9M | 183.7M | 164.3M |
| Selling & Marketing Expense | 853.5M | 850.3M | 767.8M | 755.9M | 717.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.7B | 1.7B | 1.8B | 1.7B | 1.5B |
| Cost and Expenses | 3.2B | 3.2B | 3.3B | 3.2B | 3.3B |
| Operating Income (EBIT) | 1.2B | 1.2B | 1.2B | 1.4B | 1.3B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 1.2B | 1.2B | 1.3B | 1.4B | 1.3B |
| Income Tax Expense | 130.2M | 136.4M | 89.8M | 138.4M | 105.0M |
| Bottom Line | |||||
| Net Income | 1.0B | 1.1B | 1.2B | 1.2B | 1.2B |
| Earnings from Cont. Ops | 1.1B | 1.1B | 1.2B | 1.2B | 1.2B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.0B | 1.1B | 1.2B | 1.2B | 1.2B |
| Per Share | |||||
| Basic EPS | CN¥1.82 | CN¥1.87 | CN¥2.07 | CN¥2.10 | CN¥2.00 |
| Diluted EPS | CN¥1.82 | CN¥1.87 | CN¥2.07 | CN¥2.10 | CN¥2.00 |
| Revenue Per Share | CN¥7.32 | CN¥7.40 | CN¥7.75 | CN¥7.67 | CN¥7.61 |
| Shares | |||||
| Basic Shares Outstanding | 576.7M | 571.1M | 577.0M | 579.7M | 583.7M |
| Diluted Shares Outstanding | 576.7M | 571.1M | 577.0M | 579.7M | 583.7M |
| Profitability Metrics | |||||
| EBITDA | — | 1.7B | 1.7B | 1.8B | 1.7B |
| D&A | — | 483.7M | 495.7M | 466.0M | 448.8M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026